RT Journal Article
T1 Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
A1 Seymour, John F
A1 Döhner, Hartmut
A1 Butrym, Aleksandra
A1 Wierzbowska, Agnieszka
A1 Selleslag, Dominik
A1 Jang, Jun Ho
A1 Kumar, Rajat
A1 Cavenagh, James
A1 Schuh, Andre C
A1 Candoni, Anna
A1 Recher, Christian
A1 Sandhu, Irwindeep
A1 Bernal-del-Castillo, Teresa
A1 Al-Ali, Haifa Kathrin
A1 Falantes, Jose
A1 Stone, Richard M
A1 Minden, Mark D
A1 Weaver, Jerry
A1 Songer, Steve
A1 Beach, C L
A1 Dombret, Herve
K1 AML
K1 AML-MRC
K1 Acute myeloid leukaemia
K1 Azacitidine
K1 Induction chemotherapy
K1 Low-dose cytarabine
K1 Myelodysplasia-related changes
K1 Response
K1 Survival
AB Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥65 years) patients in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC. We compared clinical outcomes for patients with AML-MRC treated with azacitidine or conventional care regimens (CCR; induction chemotherapy, low-dose cytarabine, or supportive care only) overall and within patient subgroups defined by cytogenetic risk (intermediate or poor) and age (65-74 years or ≥75 years). The same analyses were used to compare azacitidine with low-dose cytarabine in patients who had been preselected to low-dose cytarabine before they were randomized to receive azacitidine or CCR (ie, low-dose cytarabine). Median overall survival was significantly prolonged with azacitidine (n = 129) versus CCR (n = 133): 8.9 versus 4.9 months (hazard ratio 0.74, [95%CI 0.57, 0.97]). Among patients with intermediate-risk cytogenetics, median overall survival with azacitidine was 16.4 months, and with CCR was 8.9 months (hazard ratio 0.73 [95%CI 0.48, 1.10]). Median overall survival was significantly improved for patients ages 65-74 years treated with azacitidine compared with those who received CCR (14.2 versus 7.3 months, respectively; hazard ratio 0.64 [95%CI 0.42, 0.97]). Within the subgroup of patients preselected to low-dose cytarabine before randomization, median overall survival with azacitidine was 9.5 months versus 4.6 months with low-dose cytarabine (hazard ratio 0.77 [95%CI 0.55, 1.09]). Within the low-dose cytarabine preselection group, patients with intermediate-risk cytogenetics who received azacitidine had a median overall survival of 14.1 months versus 6.4 months with low-dose cytarabine, and patients aged 65-74 years had median survival of 14.9 months versus 5.2 months, respectively. Overall response rates were similar with azacitidine and CCR (24.8% and 17.3%, respectively), but higher with azacitidine versus low-dose cytarabine (27.2% and 13.9%). Adverse events were generally comparable between the treatment arms. Azacitidine may be the preferred treatment for patients with AML-MRC who are not candidates for intensive chemotherapy, particularly patients ages 65-74 years and those with intermediate-risk cytogenetics. 
PB BioMed Central Ltd.
YR 2017
FD 2017-12-14
LK http://hdl.handle.net/10668/11907
UL http://hdl.handle.net/10668/11907
LA en
NO Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 2017 Dec 14;17(1):852.
DS RISalud
RD Apr 19, 2025